BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34435512)

  • 1. SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylation.
    Hu H; Wu D; Liu X; Yu H; Xu J; Cai W; Huang Y; Bai R; Zhang J; Gu Y; Zheng S; Ge W
    Epigenomics; 2021 Aug; 13(16):1269-1282. PubMed ID: 34435512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma.
    Luo HL; Chiang PH; Huang CC; Su YL; Sung MT; Tsai EM; Lin CS; Chiang PH
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.
    Zhang HP; Wu J; Liu ZF; Gao JW; Li SY
    Biomed Res Int; 2022; 2022():1398268. PubMed ID: 35111844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance of reduced SPARCL1 expression in human breast cancer.
    Cao F; Wang K; Zhu R; Hu YW; Fang WZ; Ding HZ
    Asian Pac J Cancer Prev; 2013; 14(1):195-200. PubMed ID: 23534723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
    Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
    J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
    Hurley PJ; Hughes RM; Simons BW; Huang J; Miller RM; Shinder B; Haffner MC; Esopi D; Kimura Y; Jabbari J; Ross AE; Erho N; Vergara IA; Faraj SF; Davicioni E; Netto GJ; Yegnasubramanian S; An SS; Schaeffer EM
    Cancer Res; 2015 Oct; 75(20):4322-34. PubMed ID: 26294211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers.
    Hu H; Zhang H; Ge W; Liu X; Loera S; Chu P; Chen H; Peng J; Zhou L; Yu S; Yuan Y; Zhang S; Lai L; Yen Y; Zheng S
    Clin Cancer Res; 2012 Oct; 18(19):5438-48. PubMed ID: 22891198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Right and left-sided colon cancers - specificity of molecular mechanisms in tumorigenesis and progression.
    Mukund K; Syulyukina N; Ramamoorthy S; Subramaniam S
    BMC Cancer; 2020 Apr; 20(1):317. PubMed ID: 32293332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Tumor Suppressor Sparcl1 with Clinical Staging and Prognosis of NSCLC.
    Zhou Y; Zhang Q
    Ann Clin Lab Sci; 2021 Nov; 51(6):756-765. PubMed ID: 34921028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPARCL1 suppresses metastasis in prostate cancer.
    Xiang Y; Qiu Q; Jiang M; Jin R; Lehmann BD; Strand DW; Jovanovic B; DeGraff DJ; Zheng Y; Yousif DA; Simmons CQ; Case TC; Yi J; Cates JM; Virostko J; He X; Jin X; Hayward SW; Matusik RJ; George AL; Yi Y
    Mol Oncol; 2013 Dec; 7(6):1019-30. PubMed ID: 23916135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishable Prognostic Signatures of Left- and Right-Sided Colon Cancer: a Study Based on Sequencing Data.
    Liang L; Zeng JH; Qin XG; Chen JQ; Luo DZ; Chen G
    Cell Physiol Biochem; 2018; 48(2):475-490. PubMed ID: 30016783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer.
    Zhang H; Widegren E; Wang DW; Sun XF
    Tumour Biol; 2011 Dec; 32(6):1225-31. PubMed ID: 21887554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon.
    Koestler DC; Li J; Baron JA; Tsongalis GJ; Butterly LF; Goodrich M; Lesseur C; Karagas MR; Marsit CJ; Moore JH; Andrew AS; Srivastava A
    Mod Pathol; 2014 Jan; 27(1):145-55. PubMed ID: 23868178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying liver metastasis-related hub genes in breast cancer and characterizing
    Chen M; Zheng W; Fang L
    PeerJ; 2023; 11():e15311. PubMed ID: 37180578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.
    Lee TB; Park JH; Min YD; Kim KJ; Choi CH
    BMC Gastroenterol; 2008 Aug; 8():33. PubMed ID: 18673531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
    Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
    BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.
    Ye H; Wang WG; Cao J; Hu XC
    Mol Med Rep; 2017 Nov; 16(5):7784-7790. PubMed ID: 28944877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors.
    Dihal AA; Boot A; van Roon EH; Schrumpf M; Fariña-Sarasqueta A; Fiocco M; Zeestraten EC; Kuppen PJ; Morreau H; van Wezel T; Boer JM
    PLoS One; 2013; 8(11):e79898. PubMed ID: 24244575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes.
    Lee MS; Menter DG; Kopetz S
    J Natl Compr Canc Netw; 2017 Mar; 15(3):411-419. PubMed ID: 28275039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers.
    Isler SG; Schenk S; Bendik I; Schraml P; Novotna H; Moch H; Sauter G; Ludwig CU
    Int J Oncol; 2001 Mar; 18(3):521-6. PubMed ID: 11179481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.